TauRx Therapeutics Ltd is a member of the TauRx Pharmaceuticals group, which is developing technology spun-out from the University of Aberdeen, Scotland. The company was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company's protein aggregation inhibitor, hydromethylthionine, targets aggregates of abnormal fibres of tau and TDP-43 proteins that form inside nerve cells in the brain. TauRx's headquarters are in Singapore and its primary research facilities are based in Aberdeen. For more information, please visit: http://www.taurx.com [http://www.taurx.com/].
References
1. Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-2477.
2. Wischik CM, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis 2015;44:705-720.
3. Wilcock GK, et al. Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimers disease: cohort analysis as modified primary outcome in a phase 3 clinical trial. J Alzheimers Dis 2018;61:435-457.
4. Gauthier S, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 2016;388:2873-2884.
5. Schelter BO, et al. Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer's disease. J Alzheimers Dis 2019;72:931-946.
6. Yamashita M, et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett 2009;583:2419-2424.
7. Harrington C, et al. Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of AlzheimerDisease. J Biol Chem 2015;290:10862-10875.
8. Baddeley TC, et al. Complex disposition of methylthioninium redox forms determines ef?cacy in tau aggregation inhibitor therapy for Alzheimer's disease. J Pharmacol Exp Ther 2015;352:110-118.
Media Contacts
Alana Keating+44(0)7795-432-022 Andrew Thomas+44(0)7803-585-254Email: Taurxpress@syneoshealth.com[mailto:Taurxpress@syneoshealth.com] Website: http://www.taurx.com [http://www.taurx.com/]
Web site: http://www.taurx.com//